Adverse effects of lumbar myelography with amipaque and dimer-X.
The adverse effects in a series of 50 lumbar myelographies with Amipaque were compared with those in a corresponding series, examined with Dimer-X. Side effects occurred in 58% of the cases examined with Amipaque and in 68% of the Dimer-X series. No seizures occurred in 58% of the cases examined with Amipaque and in 68% of the Dimer-X series. No seizures occurred in either series but slight fibrillations of fasciculations appeared in 2 Dimer-X patients. Hyperreflexia of the legs was recorded in 22% of the Amipaque and in 36% of the Dimer-X cases. Other adverse reactions to the media were mild to moderate. Some burst activity, but no definite paroxysmal abnormality was noted in EEG recordings in 2 Amipaque cases. The low epileptogenicity of Amipaque has ensured a wider safety margin of lumbar myelography.
D000328:Adult; D000368:Aged; D001921:Brain / Q000187:drug effects*; D003975:Diazepam / Q000627:therapeutic use; D004341:Drug Evaluation; D004569:Electroencephalography; D005260:Female; D005334:Fever / Q000139:chemically induced; D006261:Headache / Q000139:chemically induced; D006801:Humans; D007463:Iodobenzoates / Q000009:adverse effects*; D007482:Iothalamate Meglumine / Q000009:adverse effects*; D007483:Iothalamic Acid / Q000031:analogs & derivatives*; D008161:Lumbosacral Region; D008297:Male; D008793:Metrizamide / Q000009:adverse effects*; D008875:Middle Aged; D009192:Myelography; D009325:Nausea / Q000139:chemically induced; D010146:Pain / Q000139:chemically induced; D011292:Premedication; D012640:Seizures / Q000139:chemically induced
D007463:Iodobenzoates; D007483:Iothalamic Acid; D003975:Diazepam; D008793:Metrizamide; D007482:Iothalamate Meglumine